Phacoemulsification Devices Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising Cataract Surgery Volume from Population Aging

The phacoemulsification devices market benefits from the sustained growth of the older population and the resulting need for cataract treatment. Global cataract prevalence among people aged 60 years and older reached 7,748.5 cases per 100,000 people in 2021. Population growth accounted for 87.4% of the increase in the cataract burden between 1990 and 2021. Japanese claims data showed that cataract surgery volumes rose above 2018 levels across age groups between fiscal 2018 and fiscal 2022, even where the population aged 65 to 74 declined. This pattern supports demand for systems and disposable procedure supplies in mature markets, while lower-resource settings require affordable systems and reliable supply chains. The phacoemulsification devices market therefore depends on both procedure access and providers’ ability to add surgical capacity.

Installed-Base-Linked Recurring Consumables Demand

A console installation creates continued demand for compatible cassettes, tubing, tips, sleeves, and procedure packs. These products are designed for the platform’s fluidics and handpiece configuration, which limits direct substitution in routine use. Consumables held 52.45% of revenue in 2026, reflecting this recurring procedural requirement. Alcon reported USD 769 million in surgical consumables revenue in the first quarter of 2026, with growth of 8% from the prior year. The phacoemulsification devices market gains resilience because each active installed system requires a fresh set of supplies for procedures. Manufacturers also have an incentive to support console upgrades because an upgrade can extend their compatible consumable relationship with the facility.

Migration of Routine Cataract Cases to Ambulatory and Office-Based Settings

Routine cataract procedures are increasingly delivered outside hospital operating rooms, particularly in the United States. Ambulatory surgery centers value compact equipment, dependable turnaround, and procedures that can be completed within high-volume daily schedules. MedPAC reported continued growth in Medicare-certified ambulatory surgery centers through 2024, showing the importance of outpatient capacity for procedural care^[1]. The Centers for Medicare & Medicaid Services expanded its covered-procedures list for ambulatory surgery centers in 2025, broadening the outpatient case mix. The phacoemulsification devices market benefits when centers can use systems across more cataract procedures and spread service costs over higher case volumes. This care shift also increases demand for simple workflows and service models suited to independent physician-owned centers.

Lower-Energy Fluidics and Intelligent Phaco Platform Innovation

Device development is focused on reducing energy inside the eye and improving control of irrigation and aspiration. Alcon launched the UNITY systems in April 2025 and stated that UNITY 4D Phaco provides up to 2 times faster nucleus removal with 41% less energy than the earlier CENTURION platform. BVI Medical launched Virtuoso in Europe during September 2026 after receiving a CE Mark under the EU Medical Device Regulation in April 2026. Bench research has identified measurable differences among phaco systems in post-occlusion surge volume and intraocular pressure recovery. These results give surgeons a practical basis to compare platforms beyond general product specifications. The phacoemulsification devices market is consequently seeing replacement decisions shaped by clinical performance, workflow requirements, and available capital.

Premium Console and Service-Contract Costs

Premium platforms require a sizable capital commitment, especially when they include active fluidics, laser compatibility, and digital surgical features. Their ongoing cost also includes authorized maintenance, proprietary components, and handpiece service. A 2026 review reported that femtosecond laser-assisted cataract surgery can face cost-effectiveness challenges in public health systems, even though it can offer advantages in complex cases. Independent ambulatory surgery centers must weigh these costs against the clinical value of upgrades in standard cases. The phacoemulsification devices market has responded with shared-access arrangements and systems designed for a smaller footprint. Higher procedure throughput may improve the economics of a console, but it does not remove the initial capital hurdle for every provider.

Shortage of Trained Ophthalmic Surgeons and Biomedical Support

Access to equipment does not by itself ensure that cataract treatment can be delivered at scale. A 2025 review identified workforce shortages, limited theater capacity, and equipment or consumable shortages as persistent barriers in low- and middle-income settings. Effective cataract surgical coverage remains limited in many countries, which shows that access and visual outcomes must improve together. Rural areas are affected more severely, where surgeons, trained support staff, maintenance capabilities, and consumable distribution are concentrated in large cities. Portable platforms can reduce some infrastructure needs, but they cannot replace surgical training. The phacoemulsification devices market depends on workforce development as well as equipment procurement in these settings.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Phacoemulsification Devices Market Segment Analysis

Consumables held 52.45% of revenue in 2026, giving them the largest phacoemulsification devices market share within the product category. Each cataract procedure requires products such as a cassette, tubing, irrigation and aspiration components, tips, sleeves, and procedure packs. Platform-specific design connects these purchases to the installed console base and gives suppliers recurring sales after an initial equipment placement. This model helps facilities standardize workflows and maintain familiar settings for surgical teams. It also encourages manufacturers to protect compatibility, supply reliability, and clinical support across their existing base. The phacoemulsification devices industry relies on this recurring demand because it stabilizes revenue between large equipment purchases.

Manufacturers are also updating disposable designs to reduce waste and improve handling. Johnson & Johnson Vision introduced SmartLOAD Delivery Technology in October 2026, pairing a reusable titanium inserter with a preloaded cartridge. The company stated that clinical evaluations showed 93% of surgeons expected fewer loading errors and 55-75% less packaging waste than competing preloaded systems. European procurement teams are also operating under the EU Medical Device Regulation, which raises the value of documented product quality and compliance. These factors make waste reduction, usability, and sterility relevant product requirements. The phacoemulsification devices market may see purchasing decisions increasingly consider the full procedure pack rather than only the unit cost of individual consumables.

Ultrasound phacoemulsification held 82.43% of revenue in 2026 and remains the leading technology in the phacoemulsification devices market. It has an established clinical history, broad service support, and a lower cost base than laser-assisted alternatives. Comparative research published in 2025 found differences in ultrasound time and fluidics performance among leading phaco systems used in routine cataract procedures^[2]. This means ultrasound remains a category with meaningful platform differentiation rather than a uniform equipment segment. In the United States, the Food and Drug Administration’s 510(k) pathway is a key clearance route for systems and modifications, while IEC 60601-2-5 addresses ultrasound safety requirements for equipment. These compliance factors can extend product development and commercialization timelines.

Femtosecond laser-assisted phacoemulsification is forecast to grow at an 8.54% CAGR through 2032, the highest rate in the technology segment. A 2026 network meta-analysis found that the five assessed laser platforms reduced cumulative dissipated energy compared with conventional phacoemulsification. The clinical case for this approach is stronger for hard nuclei, white cataracts, shallow anterior chambers, and posterior polar cataracts. Cost and access remain barriers to wider use in standard cases. The Federal Trade Commission’s intervention against Alcon’s proposed LENSAR acquisition preserved separate competition between major laser-assisted cataract surgery suppliers^[3]. The phacoemulsification devices industry therefore continues to use clinical differentiation and product integration as major competitive tools.

Hospitals held 64.65% of revenue in 2026, the largest share among end users. They manage complex cataract cases, teaching programs, and combined phaco-vitrectomy procedures that may require higher-capability systems. Their procurement cycles are often formal and multiyear, which can make replacement demand predictable but slow. Hospital systems can also use combined platforms across cataract and retinal work, supporting higher average equipment values. Ophthalmic clinics occupy a middle position and often prefer standalone systems that support efficient cataract workflows. The phacoemulsification devices market continues to depend on hospitals for premium placements and complex procedure capability.

Ambulatory surgery centers are forecast to grow at a 9.32% CAGR through 2032, the strongest rate in the end-user segment. Their model places a premium on short setup times, simple service needs, and consistent results across high daily case loads. MedPAC has documented the ongoing role of ambulatory surgery centers in Medicare-funded procedural care. Coverage policy also supports the trend because the covered-procedures list has expanded for the outpatient setting. Manufacturers are responding with smaller systems and configurations that are easier to fit into ambulatory workflows. The phacoemulsification devices market can gain from this shift when systems offer sufficient capability without the cost and complexity of large hospital-focused consoles.

Cataract surgery accounted for 84.65% of revenue in 2026 and remains the central application for the phacoemulsification devices market. Cataract burden rises with age, which makes procedure demand more durable than demand tied to elective vision correction. Premium intraocular lens adoption is also changing the expectations surrounding cataract procedures. Surgeons increasingly require accurate fragmentation, stable fluidics, and data-supported planning for cases involving astigmatism or advanced lens options. Combined phacovitrectomy and secondary lens removal remain smaller applications that require specialized configurations. This breadth of applications supports demand for both dedicated cataract systems and dual-function platforms.

Refractive lens exchange is forecast to grow at an 8.65% CAGR through 2032. It serves patients seeking reduced dependence on glasses and may use advanced intraocular lenses and detailed planning tools. The procedure’s growth supports systems that can deliver careful lens fragmentation and integrate with imaging or guidance systems. It also links device demand more closely to premium surgical workflows, where patient expectations and surgeon preferences influence purchasing. Bausch + Lomb described premium intraocular lenses as an important contributor to surgical performance in its 2025 investor presentation. The phacoemulsification devices market may therefore see greater interest in platforms that support both standard cataract care and refractive-focused procedures.

Geography Analysis

North America

North America held 41.32% of revenue in 2026, the largest regional share. The region has established reimbursement pathways, a large installed base of premium systems, and extensive ambulatory surgery center capacity. The United States remains important for premium cataract workflows and physician-owned outpatient centers. Medicare policy has a direct effect on facility economics and equipment replacement decisions. MedPAC continues to track ambulatory surgical center services, reflecting their place within the Medicare program. Alcon launched UNITY Cataract System in Canada during 2026 following Health Canada approval for UNITY VCS in 2025. These launches show that the region remains a key location for adoption of high-performance surgical platforms.

Asia-Pacific

Asia-Pacific is forecast to grow at a 6.43% CAGR through 2032, making it the fastest-growing regional segment. The region carries a high cataract burden, particularly in South Asia, where age-standardized prevalence is high among adults aged 60 years and older. Growth depends on wider access to trained surgeons, operating rooms, maintenance services, and consistent consumable supply. Government-supported eye care capacity can create demand for mid-tier systems that are suitable for high-volume settings. Workforce shortages and rural access gaps remain material constraints across several countries. Japan adds a mature demand profile, where claims data show sustained cataract surgery activity despite demographic changes. 

Europe, Middle East and Africa, and South America

Europe has strong public-payer coverage and a dense network of ophthalmic hospitals and clinics, which supports demand for advanced systems and consumables. EU Medical Device Regulation requirements can raise documentation and compliance demands for smaller suppliers. BVI Medical received a CE Mark under the regulation for Virtuoso during 2026. Zeiss also launched the DORC EVA NEXUS cataract configuration in select European markets in 2026. Middle Eastern and African settings have large unmet needs, where the World Health Organization is supporting regional eye hospital networks to strengthen specialized capacity. South American demand is shaped by private ophthalmic clinics and the gradual spread of advanced cataract procedures in major urban centers. These mixed regions require different pricing, service, and training approaches rather than a single commercial model.